is compound semaglutide the same as wegovy Diabetes advocacy group discourages use of compounded GLP-1 drugs Novo asks FDA to prevent

To qualify for Wegovy, youll typically need one of the following: A BMI of 30 or higher (classified as obesity ), or A BMI of 27 or higher with at least one weight-related health condition Weight-related conditions may include: High blood pressure (hypertension) High cholesterol (dyslipidemia) Type 2 diabetes Heart disease Obstructive sleep apnea Polycystic ovary syndrome ( PCOS ) In addition, in March 2024 the FDA expanded Wegovys approval to include reducing the risk of major cardiovascular events like heart attac k, stroke, and cardiovascular death in adults with cardiovascular disease plus overweight or obesity

In heart failure patients, there was a lack of changes in cardiac imaging parameters correlates with the lack of impact on outcomes among patients with pre-existing heart failure in major GLP-1 receptor agonist trials

We want to hear about the companies you love and the companies you wish you never used

Early treatments allow baseline photos and proactive planning

Off the table

Among those who continued tirzepatide, 89.5 percent maintained at least 80 percent of their weight loss